Related Experiment Video

Updated: May 31, 2025

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

7.6K

GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and

Shikha Patel1, Bhagawati Saxena2, Priti Mehta1

  • 1Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, Ahmedabad 382481, India.

Pharmaceuticals (Basel, Switzerland)
|January 25, 2025
PubMed

Insights

GnRH antagonists offer a revolutionary treatment for reproductive cancers and hormone-dependent diseases by blocking the gonadotropin-releasing hormone receptor (GnRH-R). These advanced therapies provide faster action and improved safety over traditional methods.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Oncology

Background:

  • Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) is implicated in the progression of reproductive malignancies.
  • GnRH antagonists represent a significant therapeutic advancement for hormone-dependent diseases.

Purpose of the Study:

  • To review the pharmacological role of GnRH in reproductive physiology and disease.
  • To emphasize structural advances in third- and fourth-generation GnRH antagonists.
  • To analyze GnRH antagonists' formulation, pharmacokinetics, efficacy, and safety.

Main Methods:

  • Literature review of GnRH antagonists.
  • Analysis of approved GnRH antagonists (Cetrorelix, Ganirelix, Abarelix, Degarelix, Teverelix).
  • Evaluation of clinical promise and future research directions.

Main Results:

  • GnRH antagonists provide fast, reversible suppression of gonadotropins by blocking GnRH-R.
  • These antagonists prevent hormonal flare, act faster, and have lower cardiovascular risks than agonists.
  • Approved antagonists like Cetrorelix and Ganirelix dominate ART, while Degarelix and Abarelix show promise in prostate cancer.

Conclusions:

  • GnRH antagonists are revolutionary for advanced prostate cancer, endometriosis, uterine fibroids, and ART.
  • Next-generation antagonists like Teverelix offer improved efficacy and safety.
  • Further research into GnRH antagonists can lead to safer, more effective treatments for complex hormonal diseases.
Keywords:
AbarelixCetrorelixDegarelixGanirelixGnRH peptide antagonistsTeverelixassisted reproductive technologiesprostate cancer

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.9K
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

11.8K

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
915
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
803